Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear pore complex protein Nup88 (NUP88)
- Target
- NUP88
- Molecular classification
- Nucleoporin, Nuclear pore complex protein, Other (cytoplasmic filament protein of the nuclear pore complex)
01
Overview
Nuclear pore complex protein Nup88 is a key nucleoporin component of the cytoplasmic filaments of the nuclear pore complex (NPC), mediating the selective transport of macromolecules between the nucleus and cytoplasm. It forms a subcomplex with NUP214 and is crucial for CRM1-mediated nuclear export. Nup88 interacts with NUP98, RAE1, and lamin A, is involved in mitotic spindle assembly, chromosome segregation, and regulation of the anaphase-promoting complex. Overexpression of Nup88 is found in a wide array of human cancers, contributing to aneuploidy and chromosomal instability. Dysfunctional Nup88 contributes to laminopathies and cancer progression
- Other names
- Nucleoporin 88Nup88NUP88MGC853088 kDa nucleoporinNucleoporin Nup88FADS4KaryoporinNuclear pore complex protein 88Nucleoporin 88kDaNuclear pore complex protein Nup88
02
Mechanism of action
Drugs or molecular interventions targeting NUP88 would likely act by modulating its role in nuclear export, mitotic progression, or interaction with associated subcomplexes (such as NUP214, NUP98, RAE1), altering chromosome segregation or mitotic checkpoint function
03
Biological functions
Nucleocytoplasmic transport regulationInteraction with nuclear export factor CRM1 (export of NES-containing cargos)Centrosome separation and mitotic spindle assemblyChromosome segregationRegulation of anaphase-promoting complex/cyclosome (APC/C) activityMaintenance of cellular homeostasisNuclear lamina organization through lamin A interaction
04
Disease associations
Cancer (especially aggressive, malignant neoplasms, and precancerous dysplasias)AneuploidyChromosomal instabilityTumorigenesisLaminopathies (via disrupted interaction with mutant lamin A)
05
Safety considerations
Potential challenges include toxicity in normal cells due to disruption of essential nucleocytoplasmic trafficking and cell division functionsOff-target effects due to broad involvement in nuclear transport and cellular homeostasisPossible exacerbation of chromosomal instability if not properly targeted
06
Interacting drugs
No direct evidence for small molecule drugs or approved therapeutics targeting NUP88 is reported in the available literature. Some experimental modulators may exist, but they are not listed in clinical databases
07
Biomarkers
Overexpression of Nup88 protein is a biomarker for many human cancers and correlates with advanced cancer stages and poor patient survival
Beyond the preview
Go deeper on Nuclear pore complex protein Nup88 (NUP88).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear pore complex protein Nup88 (NUP88).